Loading...
•
Sep 30, 2024
Cardiff Oncology Q3 2024 Earnings Report
Cardiff Oncology announced third quarter results and provided a business update.
Key Takeaways
Cardiff Oncology reported its third quarter 2024 financial results, highlighting the publication of positive Phase 2 trial results in the Journal of Clinical Oncology and the expected initial data readout from the first-line RAS-mutated mCRC randomized CRDF-004 trial by the end of 2024. The company's cash resources are projected to fund operations into Q1 2026.
Phase 2 clinical trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC were published in the Journal of Clinical Oncology.
Initial data readout from the first-line RAS-mutated mCRC randomized CRDF-004 trial is expected by the end of 2024.
Cardiff Oncology had approximately $57.7 million in cash, cash equivalents, and short-term investments as of September 30, 2024.
Current cash resources are expected to fund operations into Q1 2026.
Forward Guidance
Cardiff Oncology anticipates several milestones, including the initial data readout from the CRDF-004 trial by the end of 2024 and funding operations into Q1 2026.
Positive Outlook
- Initial data readout from first-line RAS-mutated mCRC randomized CRDF-004 trial expected by the end of 2024
- Current cash resources are sufficient to fund operations into Q1 2026
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...